Multisystem inflammatory syndrome in children and adults
Rare disease
Yes
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Multisystem inflammatory syndrome in children and adults
- multisystem inflammatory syndrome in children and adults
- MIS-C/A
- Disease mechanisms
- Acquired
- Severity
- Unknown
- MONDO ID
- MONDO:0035375
- Parent condition
- MONDO:0100320
Related records
Broader conditions (7)
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Post-COVID-19 disorder
- Post-infectious disorder
- Post-viral disorder
Narrower conditions (2)
- COVID-19–associated multisystem inflammatory syndrome in adults
- COVID-19–associated multisystem inflammatory syndrome in children
Trials (58)
- 2-HOBA Supplementation in People With Elevated Lipoprotein(a)
- 24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized Trial
- A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
- A Multi-center, Prospective, Observational Study to Describe the siTuation of Blood Lipid mAnagement Among the Population With hypeRtension and/or Type 2 diabeTes in Community Health Center
- A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a)
- A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events
- A Study of DII235 in Adults With Elevated Lipoprotein(a)
- A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
- A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
- A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]
- A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
- A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
- AI-assisted CT for Risk Stratification in Coronary Artery Disease (ACTION)
- An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
- Argentine Registry of Lp(a)
- Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
- Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- Atlantic Lipid Lowering Treatment Optimization Program